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Background: Pegylated granulocyte colony-stimulating factor (G-CSF; pegfilgrastim) is a longer-acting form of
G-CSF, whose effects on dendritic cell (DC) and regulatory T cell (Treg) mobilization, and on the in vivo and ex vivo
release of immune modulating cytokines remain unexplored.
Methods: Twelve patients with gynecological cancers received carboplatin/paclitaxel chemotherapy and single-
dose pegfilgrastim as prophylaxis of febrile neutropenia. Peripheral blood was collected prior to pegfilgrastim
administration (day 0) and on days +7, +11 and +21, to quantify immunoregulatory cytokines and to assess type 1
DC (DC1), type 2 DC (DC2) and Treg cell mobilization. In vitro-differentiated, monocyte-derived DC were used to
investigate endocytic activity, expression of DC maturation antigens and ability to activate allogeneic T-cell
proliferation.
Results: Pegfilgrastim increased the frequency of circulating DC1 and DC2 precursors. In contrast, CD4
+FoxP3
+
bona fide Treg cells were unchanged compared with baseline. Serum levels of hepatocyte growth factor and
interleukin (IL)-12p40, but not transforming growth factor-b1 or immune suppressive kynurenines, significantly
increased after pegfilgrastim administration. Interestingly, pegfilgrastim fostered in vitro monocytic secretion of IL-
12p40 and IL-12p70 when compared with unconjugated G-CSF. Finally, DC populations differentiated in vitro after
clinical provision of pegfilgrastim were phenotypically mature, possessed low endocytic activity, and incited a
robust T-cell proliferative response.
Conclusions: Pegfilgrastim induced significant changes in immune cell number and function. The enhancement of
monocytic IL-12 secretion portends favorable implications for pegfilgrastim administration to patients with cancer,
a clinical context where the induction of immune deviation would be highly undesirable.
Background
Granulocyte colony-stimulating factor (G-CSF) can be
administered to healthy individuals donating hemato-
poietic stem cells (HSC) for transplantation and to can-
cer patients with the aim to prevent and/or treat
chemotherapy-induced neutropenia. Currently, primary
prophylaxis with G-CSF is recommended in patients at
high risk for febrile neutropenia based on age, medical
history, disease characteristics and myelotoxicity of the
chemotherapy regimen.
Filgrastim is a recombinant human G-CSF derived
from Escherichia coli. Filgrastim has a short elimination
half-life and requires daily subcutaneous injections for
each chemotherapy cycle. The inconvenience associated
with filgrastim administration has prompted the devel-
opment of its covalent conjugation with monomethoxy-
polyethylene glycol (PEG) to obtain a longer-acting form
(pegfilgrastim). The covalent attachment of PEG to the
N-terminal amine group of the parent molecule
increases its size, so that neutrophil-mediated clearance
predominates over renal clearance in elimination of the
drug, extending the median serum half-life of pegfilgras-
tim to 42 hours, compared with 3.5-3.8 hours for
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ing on the absolute neutrophil count (ANC), which in
turn reflects the ability of pegfilgrastim to sustain neu-
trophil production. The PEG group in the pegfilgrastim
molecule is a relatively inert adduct and is expected not
to alter granulocyte function significantly compared
with filgrastim. In line with this assumption, pegfilgras-
tim retains the same biological activity as filgrastim, and
binds to the same G-CSF receptor, stimulating neutro-
phil proliferation, differentiation and activation.
The long-term effects of long-acting growth factors
such as pegfilgrastim are unknown. Because an increas-
ing number of healthy donors and cancer patients are
exposed to pharmacologic doses of G-CSF, a thorough
understanding of G-CSF effects is imperative to safe-
guard donor and patient safety. In this respect, there is
accumulating evidence that the biological activities of
G-CSF are not limited to the myeloid lineage but extend
to cell types and cytokine networks implicated in
inflammation, immunity and angiogenesis [2]. Initial
s t u d i e si nm i c es u p p o r t e dar o l ef o rG - C S Fi ni m m u n e
deviation towards T helper type 2 (Th2) cytokine pro-
duction [3]. In humans, G-CSF increases interleukin
(IL)-4 release and decreases interferon (IFN)-g produc-
tion [4], induces immune modulatory genes in T cells,
including the Th2 master transcription factor GATA-3
[5], and promotes the differentiation of type 1 regulatory
T cells (Treg), endowed with the ability to release IL-10
and transforming growth factor (TGF)-b1, and to sup-
press T-cell proliferation in a cytokine-dependent man-
ner [6]. Furthermore, G-CSF induces the release of
hepatocyte growth factor (HGF) [7], a pleiotropic cyto-
kine that inhibits dendritic cell (DC) maturation [8] and
down-regulates immune responses in vivo [9]. Finally,
G-CSF mobilizes human type 2 DC (DC2) [10] and pro-
motes the in vitro differentiation of regulatory DC
through the stimulation of IL-10 and IFN-a production
[11]. On a molecular level, G-CSF may determine mito-
chondrial dysfunction and proliferation arrest in T cells
[12]. G-CSF-mobilized monocytes acquire the ability to
release large quantities of immunosuppressive IL-10 and
impair the induction of CD28-responsive complex in
CD4
+ T cells [13]. Similar to filgrastim, pegylated G-
CSF enhances the lipopolysaccharide (LPS)-stimulated
production of immune suppressive IL-10 and favorably
affects the clinical course of graft-versus-host disease
(GVHD) in mice [14].
It is presently unknown whether pegylated G-CSF
modulates human T-cell and DC function to a similar
extent as unconjugated G-CSF. The hypothesis that the
two formulations of G-CSF may target distinct cell
populations in vivo and that, in spite of structural simi-
larities, the spectrum of their biological activities may
diverge is supported by investigations with human
pegfilgrastim-mobilized HSC, which display unique fea-
tures compared with HSC mobilized by filgrastim [15].
The present study provides evidence that pegylated G-
CSF mobilizes both DC1 and DC2 precursors and, at
variance with filgrastim, promotes monocytic IL-12
release. These findings portend favorable implications
for pegfilgrastim administration to cancer patients.
Methods
Patient eligibility and treatment plan
The study population was comprised of 12 patients with
gynecological malignancies (7 ovarian, 4 endometrial, 1
cervical cancer) ranging in age from 38 to 78 years
(median age = 68 years). All patients received a conven-
tional chemotherapeutic regimen, consisting of carbo-
platin (AUC5) and paclitaxel (175 mg/square meter).
The patients’ clinical characteristics are summarized in
Table 1. After the completion of chemotherapy, patients
were given a single dose (6 mg) of subcutaneous pegfil-
grastim (Neulasta®; Amgen Dompè, Milan, Italy), as pro-
phylaxis of febrile neutropenia. The investigations were
approved by the Institutional Review Board. A retro-
spective analysis of 7 registrational clinical trials that
examined the safety and efficacy of pegfilgrastim indi-
cated that serum pegfilgrastim concentrations are con-
sistently sub-therapeutic (< 2 ng/ml) by day +12 from
the commencement of treatment [16]. Taking advantage
of this knowledge, we collected blood samples from
each consented patient on day 0 (the day before che-
motherapy), and on days +7, +11 and +21.
A control group of 7 patients with gynecological
malignancies received the same carboplatin/paclitaxel
chemotherapy regimen, followed by daily filgrastim (5
μg/kg of body weight) from day +2 to day +10. Blood
samples for ex vivo s t u d i e sw e r ed r a w no nd a y0( t h e
day before chemotherapy) and on days +7, +11 (24
hours after the last filgrastim administration) and +21.
For both groups of patients, serum was obtained by cen-
trifugation at 4,000 rpm for 15 minutes shortly after
blood collection, was divided into aliquots and stored at
-80°C until used. Peripheral blood mononuclear cells
(PBMC) were separated by Ficoll-Hypaque density gra-
dient centrifugation, as previously reported [11], and
were used as detailed below.
Generation of monocyte-derived DC (Mo-DC) and
evaluation of DC endocytic activity
CD14
+ monocytes were purified by negative selection
(Monocyte Isolation Kit II, Miltenyi Biotec, Bergisch
Gladbach, Germany) and were cultured in RPMI-1640
medium for 6 days at 37°C under serum-free conditions
(10% BIT-9500; StemCell Technologies, Vancouver, BC)
but in the presence of 500 IU/ml recombinant human
GM-CSF and 25 ng/ml IL-4 (both cytokines were from
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the DC preparations were matured with 500 IU/ml
tumour necrosis factor-a (TNF-a; R&D Systems) for 48
hours. Patient serum obtained before (pre-G) or after G-
CSF administration (post-G) was supplemented to
freshly isolated monocytes at 20% (v/v). In selected
experiments, monocytes were stimulated in vitro with
LPS (1 μg/ml) for 24 hours, prior to the measurement
of secreted IL-12p40/IL-12p70 and IL-10 by ELISA.
To evaluate DC endocytic activity [17], monocyte-
derived DC populations were suspended in culture med-
ium supplemented with 10% fetal calf serum (FCS) in
the presence of 100 μg/ml FITC-dextran (Sigma Chemi-
cal Co., St. Louis, MO) for 1 hour at 37°C. Control DC
cultures were pulsed with FITC-dextran at 4°C, as pre-
viously detailed [8]. The extent of FITC-dextran incor-
poration was expressed as the ratio between the mean
fluorescence intensity (MFI )o fs a m p l e sk e p ta t3 7 ° C
and the MFI of samples cultured at 4°C, as detailed in
the Figure legends.
T-cell isolation and primary MLR
CD4
+ T cells were isolated from the peripheral blood
with an indirect magnetic labeling system (CD4
+ TC e l l
Isolation Kit II; Miltenyi Biotec). Briefly, PBMC were
labeled with a cocktail of biotin-conjugated antibodies
against CD8, CD14, CD16, CD19, CD36, CD56, CD123,
TCR g/δ and CD235a. Anti-biotin microbeads were used
for depletion, yielding a population of highly pure,
untouched CD4
+ T cells. CD25 microbeads II (Miltenyi
Biotec) were subsequently used for positive selection or
depletion of CD25




- T cells were re-suspended in RPMI-1640
containing carboxyfluorescein-diacetate succinimidyl-
ester (CFDA-SE, 2.5 μM; Molecular Probes, Eugene,
OR) for 10 minutes at 37°C. To quench the labeling
process, an equal volume of FCS was added. After wash-
ings in RPMI-1640 medium supplemented with 10%
FCS, CD4
+CD25
- T cells were activated with the mixed
leukocyte reaction (MLR), as reported elsewhere [6].
Briefly, 5 × 10
4 allogeneic CD4
+CD25
- T cells were cul-
tured with fixed numbers of irradiated (25 Gy) DC or
monocytes for 7 days, in RPMI-1640 medium supple-
mented with 20% BIT serum substitute. In selected
experiments, serum from patients given either pegfil-
grastim or filgrastim was supplemented at 20% (v/v) to
the allogeneic MLR containing T cells and monocytes/
DC from third-party healthy donors, as previously
detailed [18].
Immunological markers, four-color flow cytometry and
data analysis
Mo-DC and monocytes were incubated for 20 minutes
at 4°C with the following FITC-, PE-, PerCP- or PE-
Cy7-conjugated monoclonal antibodies (mAb): CD1a,
CD11c, CD14, CD80, CD86, CD83 (Caltag Laboratories,
Burlingame, CA), HLA-DR, CD11c and IL-3 receptor a-
chain or CD123 (BD Biosciences, Mountain View, CA),
immunoglobulin-like transcript 3 (ILT3), DC-SIGN
(DC-specific ICAM-3 grabbing non-integrin; CD209;
Immunotech, Marseille, France), or with the appropriate
fluorochrome-conjugated, isotype-matched irrelevant
mAb to establish background fluorescence.
To monitor DC mobilization, peripheral blood sam-
ples were stained with a cocktail of FITC-conjugated
mAb directed against lineage-specific antigens (CD4,
CD14, CD16, CD19, CD20, CD56; Lineage Cocktail 1,
BD Biosciences), and with anti-CD123, anti-HLA-DR
and anti-CD11c mAb (BD), in order to discriminate
Table 1 Patients’ characteristics
Patient Tumor (histotype) FIGO Stage Tumor grade Number of previous chemotherapy cycles
UPN #1 Endometrial carcinoma (endometrioid) Ic G3 4
UPN #2 Endometrial carcinoma (serous) IV G3 5
UPN #3 Ovarian carcinoma (serous) IIIb G3 4
UPN #4 Cervical carcinoma (squamous) Ib2 G2 2
UPN #5 Ovarian carcinoma (serous) IIIc G3 3
UPN #6 Endometrial carcinoma (mixed) Ic G2 1
UPN #7 Ovarian carcinoma (serous) Ic G3 4
UPN #8 Ovarian carcinoma IIIc G3 4
UPN #9 Ovarian carcinoma (serous) IIIc G3 4
UPN #10 Endometrial carcinoma (endometrioid) Ic G3 4
UPN #11 Ovarian carcinoma (endometrioid) IIIc G3 3
UPN #12 Ovarian carcinoma (endometrioid) IIIb G2 4
The demographic characteristics of the 12 patients enrolled in this study are shown. Patients had not received any chemotherapy in the 21 days preceding the
commencement of the carboplatin/paclitaxel regimen (see Materials and Methods for further details). FIGO = International Federation of Gynecologya n d
Obstetrics. UPN = Unique Patient Number.
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with ammonium chloride lysis buffer for 5 minutes to
remove residual red blood cells. Unfractionated whole
blood samples were gated on the basis of forward and
side scatter characteristics. After gating on lineage
-HLA-
DR
+ events, two populations of DC were identified, cor-
responding to HLA-DR
+CD11c
+ DC (DC1) and HLA-
DR
+CD123
+ DC (DC2), as previously published [10].
The proportion of DC1 and DC2 within lineage
-/dim
cells was enumerated and expressed as a percentage of
total leukocytes.
The analysis of CFDA-SE fluorescence in cell prolif-
eration tracking assays was performed with the prolif-
eration wizard of the ModFit™ LT 2.0 software (Verity
Software House Inc., Topsham, ME). Replication data
were expressed in terms of proliferation index (PI),
which was calculated as previously detailed [12].
The frequency of CD4
+FoxP3
+ Treg cells in the per-
ipheral blood of G-CSF-treated patients and in MLR
cultures was estimated with an anti-FoxP3 mAb
(PCH101 clone; eBioscience, San Diego, CA). Cells were
initially stained with fluorochrome-conjugated anti-CD4
and anti-CD25 mAb (BD Biosciences), followed by
sequential cell fixation and permeabilization and by
labeling with the Alexa-Fluor® 488-conjugated anti-
human FoxP3 mAb.
All samples were run through a FACS Canto® flow
cytometer (BD Biosciences) with standard equipment.
Analysis of cytokine production
IL-12p40, IL-12p70, IL-10, TGF-b1 and HGF levels in
patient serum and in culture supernatants were quanti-
fied by ELISA, using commercially available reagents
(R&D Systems). The limits of detection were < 15 pg/ml
IL-12p40, 0.625 pg/ml IL-12p70, 7.8 pg/ml IL-10, 7 pg/
ml TGF-b1 and <40 pg/ml HGF.
HPLC measurement of tryptophan (Trp) and kynurenine
(Kyn)
Quantification of serum Trp and Kyn was obtained using
reverse-phase (RP)-HPLC. The chromatographic proce-
dure was similar to a method previously described, with
minor modifications [19]. In brief, sample aliquots (100
μL) were deproteinized with HClO4 (0.3 M final concen-
tration). After centrifugation (14,000 rpm for 15 min-
utes), the supernatants were spiked with 50 μM3 - L -
nitrotyrosine and analyzed using a ReproSil-Pur C18-AQ
(4 × 250 mm, 5 μM granulometry) RP-HPLC column
(Dr. Maisch GmbH, Ammerbuch-Entringen, Germany),
using a double-pump HPLC apparatus from Jasco
(Tokyo, Japan) equipped with a mod. 2070 UV spectro-
photometric detector and a FP-2020 fluorescence detec-
tor. Both detectors were connected in series to allow
simultaneous measurements. The chromatographic peaks
were detected by recording UV absorbance at 360 nm
and emission fluorescence at 366 nm, after excitation at
286 nm. The elution solvent was: 2.7% CH3CN in 15 mM
acetate buffer, pH 4.00 (both HPLC-grade from Fluka,
Milan, Italy). To control the set-up and for peak quantifi-
cation, Borwin 1.5 and MS Excel software were used. The
concentrations of components were calculated according
to peak heights and were compared both with 3-nitro-L-
tyrosine as the internal standard and with the reference
curves constructed with Kyn and L-Trp, both purchased
from Sigma-Aldrich.
Statistical analysis
The approximation of data distribution to normality was
tested preliminarily using statistics for kurtosis and sym-
metry. Data were presented as median and interquartile
range, and comparisons were performed with the Mann-
Whitney test for paired or unpaired data, or with the
Kruskal-Wallis test with Dunn’s correction for multiple
comparisons, as appropriate. The criterion for statistical
significance was defined as p ≤ 0.05.
Results
Effects of pegylated G-CSF on leukocyte subsets
Patients were initially evaluated for their white blood
cell (WBC) and absolute neutrophil count (ANC) in
response to pegfilgrastim. As depicted in Figure 1, both
the WBC count and the ANC significantly increased on
day +11 compared with pre-treatment values (p =
0.0002 and p = 0.033, respectively) and returned to
baseline on day +21. Notably, filgrastim promoted a
greater increase of WBC and neutrophils compared with
pegfilgrastim, peaking on day +11 after the commence-
ment of cytokine treatment (p = 0.0085 and p = 0.028
compared with baseline, respectively). Specifically, a
median of 16.5 × 10
3 WBC/μlo fb l o o d( r a n g e7 . 7 4 -
36.82) were counted in day +11 samples from filgras-
tim-treated patients compared with 11.64 × 10
3 WBC/μl
of blood (range 6.88-15.78) in patients given pegfilgras-
tim (p < 0.05). Similarly, the ANC was significantly
higher on day +11 after filgrastim administration (13.6 ×
10
3/μl, range 5.54-31.81) compared with the pegfilgras-
tim group (7.91 × 10
3/μl, range 3.39-13.6; p < 0.05).
It has been previously shown that unconjugated G-
CSF increases the number of lymphoid progenitors,
mature lymphocytes and monocytes when administered
to healthy HSC donors [20]. In our cohort of cancer
patients, both pegfilgrastim and filgrastim significantly
enhanced lymphocyte (p = 0.0002 and p = 0.0093,
respectively) and monocyte counts (p < 0.0001 and p =
0.013, respectively) compared with baseline, peaking on
day +11 from the commencement of cytokine treatment
(Figure 1). Again, monocyte counts were significantly
higher in patients treated with daily filgrastim (0.8 × 10
3
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patients given pegfilgrastim (0.57 × 10
3 cells/μl, range
0.21-0.93; p = 0.04). Neither lymphocyte nor monocyte
count at baseline differed significantly in the two patient
cohorts (lymphocyte count = 1.69 × 10
3 cells/μl, range
0.8-2.24; and 1.21 × 10
3 cells/μl, range 0.45-2.54, in the
filgrastim and pegfilgrastim group, respectively; mono-
cyte count = 0.25 × 10
3 cells/μl, range 0.05-0.35; and
0.23 ± 0.06 × 10
3 cells/μl, range 0.03-0.89, in the filgras-
tim and pegfilgrastim group, respectively), suggesting
that the sharper elevation of monocyte counts likely
reflected an intrinsic ability of filgrastim to mobilize
cells of the monocytic lineage. The observed changes in
leukocyte subsets were transient, as indicated by the
recovery of pre-treatment values by day +21 (Figure 1).
Importantly, both the absolute number and the fre-
quency of lymphocytes and monocytes increased as a
result of pegfilgrastim administration (Figure 1), indicat-
ing the occurrence of mobilization and/or recruitment
from peripheral sites into the circulation. However, the
relative distribution of CD4
+ T cells, CD8
+ T cells,
CD19
+ B cells and NK cells (defined as CD3
-CD16
+CD56
+ cells) within the lymphocyte population was
unaffected by pegfilgrastim administration (data not
shown). In sharp contrast to pegfilgrastim, filgrastim
was unable to affect the frequency of lymphocytic and
monocytic cells, as shown in Figure 1. The percentage
of lymphocytes within total leukocytes was even lower
on days +7 and +11 after filgrastim administration com-
pared with baseline. Not unexpectedly, treatment with
pegfilgrastim was associated with the mobilization of
CD34-expressing HSC, which peaked on day +11 from
cytokine treatment (4.2 cells/μl, range 2-23.1, compared
with 0.9 cells/μl, range 0.5-10.4, at baseline; p <0 . 0 5 )
and declined to pre-treatment values by day +21 (0.8
cells/μl, range 0.25-2).
Mobilization of DC subsets and Treg cells
We next investigated whether pegfilgrastim induced
changes in the frequency of circulating DC precursors.
Cells were initially gated based on lack of expression of
surface antigens associated with lineage differentiation,
as detailed in Materials and Methods. A representative
flow cytometry profile is shown in Figure 2A. Lineage
-
cells were then analyzed for their expression of HLA-
DR in association with CD11c (DC1) or CD123 (DC2),
recognizing the IL-3 receptor a chain. Figure 2B depicts
the cumulative frequency of DC1 and DC2 cells within
Figure 1 Changes in leukocyte subsets in patients receiving growth factor support. Leukocytes, neutrophils, monocytes and lymphocytes
were enumerated with automated hematology analyzers before chemotherapy (day 0) and on days +7, +11 and +21 from G-CSF administration.
Bars depict median values. The results of statistical comparisons among baseline and post-treatment samples and between the two study
groups have been detailed in the main text.
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either pegfilgrastim or daily filgrastim. In both cohorts
of patients, cytokine administration translated into
increased percentages of DC1 and DC2 cells, albeit with
a different kinetics. Specifically, DC1 precursor cells
were detected at higher frequency on day +7 after the
commencement of pegfilgrastim (p < 0.05) and declined
thereafter, whereas DC2 precursor cells reached a peak
value on day +11 (p < 0.05). In contrast, daily filgrastim
preferentially mobilized DC1 compared with DC2 cells,
and both DC populations peaked at day +11 (p <0 . 0 1
and p < 0.05 for DC1 and DC2, respectively), corre-
sponding to the day after drug discontinuation (Figure
2B).
Because FoxP3
+ Treg cells are heterogeneous in
humans and FoxP3-expressing cells have been detected
both within CD4
+CD25
+ and within CD4
+CD25
- T-cell
populations [21], we measured the frequency of bona
fide Treg cells based on their CD4
+FoxP3
+ phenotype.
Treg cells at baseline were comparable in patients given
pegfilgrastim (5.2%, range 1.7-8.1) and in patients trea-
ted with daily unconjugated G-CSF (4.9%, range 3.2-
Figure 2 Mobilization of DC precursors and Treg cells in patients receiving growth factor support. The frequency of DC1 (lineage
-HLA-DR
+CD11c
+) and DC2 (lineage
-HLA-DR
+CD123
+) precursors and that of CD4
+FoxP3
+ Treg cells was estimated by flow cytometry, as detailed in
Materials and Methods. Panel A: Gating strategy for the enumeration of DC1 and DC2 precursors. Cells were initially gated based on lack of
surface antigens associated with blood cell lineages. The co-expression of HLA-DR and CD11c or CD123 is shown in one patient given
pegfilgrastim, and is representative of 12 independent experiments. Panel B: Cumulative frequency of DC1 (empty bars) and DC2 (black bars) in
patients given pegfilgrastim or filgrastim. Median values and interquartile range are shown. *p < 0.05 compared with baseline. **p < 0.01
compared with baseline. Panel C: Boxes and whiskers depicting median values and interquartile range. *p = 0.01 compared with healthy
controls (black bar); **p = 0.0009 compared with healthy controls (black bar). The Kruskal-Wallis test with Dunn’s correction for multiple
comparisons was used for statistical analyses. Panel D: Representative flow cytometry profile from one patient treated with pegfilgrastim.
Quadrants were set according to the proper isotypic control (not shown). The percentage of CD4
+FoxP3
+ T cells in indicated.
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teers (2.9%, range 2.3-4; nr of subjects = 8; p <0 . 0 1 ) ,i n
agreement with other reports describing Treg expansion
in the immunosuppressive milieu of patients with gyne-
cological malignancies [22]. As shown in Figure 2C, a
trend towards higher percentages of Treg cells was docu-
mented in samples collected after either pegfilgrastim or
filgrastim administration. In the pegfilgrastim group, a
median of 7.6% (range 5-9.6) CD4
+ T cells co-expressed
FoxP3 on day +21 from cytokine administration com-
pared with 5.2% (range 1.7-8.1) at baseline, but this dif-
ference failed to achieve statistical significance. Similarly,
5.8% (range 5.7-6.9) CD4
+FoxP3
+ T cells were detected
at late time-points after filgrastim administration com-
pared with 4.97% (range 3.2-7.7) at baseline (p =N S ) .
Notably, the percentage of Treg cells at any time-point
after filgrastim treatment significantly exceeded that
measured in healthy controls (Figure 2C). A representa-
tive experiment aimed at detecting Treg cells for one
patient given pegfilgrastim is depicted in Figure 2D.
Cytokine measurements and Trp/Kyn ratio
It is now recognized that the balance between IL-12 and
IL-10 produced by the antigen presenting cell compart-
ment dictates the outcome of an immune response, with
IL-12 release leading to robust T-cell priming and IL-10
secretion primarily mediating the induction of T-cell
unresponsiveness [23]. As shown in Figure 3A, serum IL-
12p40 levels significantly increased after pegfilgrastim
administration and returned to baseline on day +21. Con-
versely, IL-12p40 slightly declined in cancer patients
given daily G-CSF, and returned to pre-treatment values
by day +11. IL-10 serum levels were consistently below
the ELISA lowest standard (7.8 pg/ml), either in patients
treated with pegfilgrastim or in those given unconjugated
G-CSF (data not shown). TGF-b and HGF play signifi-
cant roles as immune modulating growth factors both
physiologically and in pathological states such as cancer.
In order to gain further insights into the immune modu-
lation exerted by G-CSF, we also measured TGF-b and
HGF levels before and after cytokine treatment. TGF-b
levels displayed minor fluctuations in the peripheral
blood of patients given either unconjugated G-CSF or
pegylated G-CSF (Figure 3A). In contrast, the administra-
tion of pegfilgrastim was associated with an increase of
serum HGF compared with baseline (Figure 3A). Impor-
tantly, serum HGF levels on day +11 were significantly
higher in patients receiving filgrastim than in those given
pegfilgrastim (p = 0.043). In both cohorts of patients,
HGF returned to pre-treatment values on day +21 from
the commencement of cytokine administration.
Because HGF may induce the expression of indolea-
mine 2,3-dioxygenase 1 (IDO1) [8], an enzyme impli-
cated in the conversion of Trp into immune suppressive
Kyn [24], we analyzed IDO1 mRNA expression in
patient monocytes and neutrophils and measured serum
Trp and Kyn levels after treatment with pegfilgrastim.
RT-PCR studies with purified monocytes and neutro-
phils indicated that mRNA signals for IDO1 were
unchanged after pegfilgrastim administration [see Addi-
tional file 1]. As shown in Additional file 1, serum Kyn
displayed minor fluctuations following pegfilgrastim
administration. It should be emphasized that Kyn levels
in 4 out of 5 patients, either at baseline or after the clin-
ical provision of pegfilgrastim, were higher than those
measured in healthy controls. Finally, serum Trp levels
were significantly lower (< 40 μM) than in healthy con-
trols (83.9 μM on average; data not shown) at any time-
point, in line with previous data on altered Trp catabo-
lism in cancer patients [24].
In order to more accurately substantiate the assump-
tion that pegfilgrastim alters the balance between IL-
12 and IL-10, monocytes, a prominent cellular source
of both IL-12 and IL-10, were magnetically purified on
day +11 from the peripheral blood of patients treated
with pegfilgrastim (24 hours before the anticipated
decline of serum pegfilgrastim concentration [16] and
coincident with maximal monocyte mobilization) and
from cancer patients treated with daily filgrastim (24
hours after the last G-CSF administration). Monocytes
were routinely > 95% pure, as evaluated by flow cyto-
metry measurements of CD14 expression (data not
shown). Equal numbers of monocytes from pre-G-CSF
and post-G-CSF samples were cultured for up to 96
hours in the presence of LPS as a stimulus. The LPS-
induced monocytic release of IL-10 increased after
pegfilgrastim administration (Figure 3B). Notably, post-
pegfilgrastim monocytes secreted considerable amounts
of IL-12p40 at any time-point in culture (Figure 3B).
In line with previous reports [25], monocytes from fil-
grastim-treated patients secreted low amounts of IL-
12p40. Intriguingly, IL-12p40 production by post-fil-
grastim monocytes was significantly lower than that
measured in post-pegfilgrastim monocyte cultures at
any time-point. To further reinforce the assumption
that pegfilgrastim, but not unconjugated G-CSF,
enhances the monocytic release of IL-12 on a per cell
basis, IL-12p70 levels were measured in supernatants
of monocytes purified from 3 patients given pegfilgras-
tim and 3 patients receiving unconjugated G-CSF. As
shown in Figure 4, post-pegfilgrastim monocytes
released significantly higher levels of IL-12p70 com-
pared with monocytes isolated from cancer patients
treated with unconjugated G-CSF.
In vitro DC phenotype and function
It has been previously shown that filgrastim indirectly
affects DC number and function, skewing in vitro DC
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assess whether soluble factors induced by pegfilgrastim
hindered DC maturation, we cultured monocytes from
healthy controls with patient serum collected either
before or after G-CSF administration. At the end of the
6-day culture period, cells were recovered and labeled
with a panel of mAb recognizing DC activation/differen-
tiation antigens. Control cultures consisted of immuno-
genic DC differentiated with GM-CSF and IL-4 under
serum-free conditions. The phenotypic and functional
features of the DC-like cells differentiated after the pro-
vision of filgrastim have been extensively reported else-
where [11] and these experiments were not further
replicated in the present study.
For technical reasons, insufficient quantities of day +7
s e r u mw e r eo b t a i n e dt ob es u p p l e m e n t e da t2 0 %v / vt o
the DC and monocyte cultures. Figure 5 thus illustrates
a representative experiment with day +11 and day +21
monocyte-derived DC preparations. Not unexpectedly,
monocytes cultured with GM-CSF and IL-4 under
serum-free conditions down-regulated CD14, were uni-
formly CD1a
+, and up-regulated costimulatory mole-
cules (CD80 and CD86) and DC maturation antigens
such as CD83 and CD209 (Figure 5A). In sharp con-
trast, monocytes cultured with either pre- or post-pegfil-
grastim serum maintained a CD14
+CD1a
- phenotype, in
accordance with previous reports on the phenotype of
human serum-supplemented DC cultures [11].
Figure 3 Ex vivo cytokine measurements and in vitro monocytic release of IL-10 and IL-12p40. Panel A: Patient serum was collected at
the indicated time-points and used to evaluate IL-12p40, TGF-b1 and HGF levels by ELISA. Bars depict median values and interquartile ranges
recorded in 12 independent experiments performed in duplicate. °p < 0.01 when comparing IL-12p40 levels on day +7 vs. day +21. °°p = 0.0036
when comparing IL-12p40 levels on day +11 vs. baseline and vs. day +21. *p = 0.0023 when comparing HGF levels on day +7 and day +11 vs.
baseline. §p = 0.0062 when comparing HGF levels on day +7 and day +11 vs. baseline and vs. day +21. Panel B: Monocytes were purified on
day +11 from the commencement of cytokine treatment, coincident with maximal mobilization into the peripheral blood. Cells (1 × 10
6) were
stimulated with 1 μg/ml LPS in complete culture medium for up to 96 hours. Supernatants were harvested daily and used to measure IL-10 and
IL-12p40 by ELISA. IL-10 and IL-12p40 levels were also estimated in 7 patients with gynecological cancers treated with daily G-CSF. Median
values and interquartile range are shown. *p < 0.01 compared with IL-12p40 levels in supernatants of post-filgrastim monocytes.
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Page 8 of 15Figure 4 In vitro monocytic release of bioactive IL-12p70. Monocytes (1 × 10
6) purified from the peripheral blood of patients given
pegfilgrastim (n = 3) or filgrastim (n = 3) were stimulated with LPS as detailed in the legend to Figure 3B. Supernatants were harvested daily
and used to measure IL-12p70 by ELISA. Each point is representative of the mean value of triplicate IL-12p70 measurements.
Figure 5 Phenotypic features of DC-like cells from patients receiving pegfilgrastim. Monocytes were purified from the peripheral blood of
patients given pegfilgrastim and were cultured in the presence of either pre-G-CSF or post-G-CSF serum (20% v/v) for 6 days, as detailed in
Materials and Methods. Control cultures consisted of immunogenic DC preparations that were differentiated with GM-CSF and IL-4 without the
provision of additional maturation stimuli (
GM4DC). Panel A: Percentage of cells staining positively for a given antigen in a representative
experiment out of 12 with similar results. Panel B: Relative expression of informative differentiation antigens. Median values and interquartile
range recorded in 12 independent experiments. *denotes a p value < 0.05 compared with the other time-points.
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post-pegfilgrastim serum differed in their expression of
costimulatory molecules. CD80 and CD86 were
expressed at significantly higher levels after culture with
post-pegfilgrastim serum, both in terms of percent posi-
tive cells and in terms of MFI (Figure 5A and 5B). In
addition, post-pegfilgrastim monocytes up-regulated the
DC maturation antigen CD209 compared with cells in
pre-G-CSF cultures (Figure 5B). ILT3 was also detected
on higher percentages of post-pegfilgrastim monocytic
cells, where its expression increased in terms of fluores-
cence intensity. Finally, CD83, CD11c and CD123 were
detected on comparable percentages of pre-G-CSF and
post-G-CSF monocytes. Taken together, phenotypic stu-
dies revealed that soluble factors contained in post-peg-
filgrastim serum promoted the acquisition of a mature
DC-like phenotype, with high expression of costimula-
tory molecules and CD209, and preserved expression of
the monocyte/macrophage antigen CD14. In line with
this, monocytes nurtured with post-pegfilgrastim serum
possessed a diminished ability to endocytose FITC-con-
jugated dextran, a measure of DC maturation status,
compared with monocytes cultured with pre-pegfilgras-
tim serum and with immature DC differentiated with
GM-CSF and IL-4, used as control for optimal incor-
poration of FITC-dextran (Figure 6A and 6B).
Effect of post-G-CSF serum on alloantigen-induced T-cell
proliferation
We finally asked whether the DC-like preparations
obtained after culture of monocytes from G-CSF-treated
patients could differentially activate the proliferation of
n a ï v ea l l o g e n e i cC D 4
+CD25
- T cells in comparison with
conventional immunogenic DC differentiated with GM-
CSF and IL-4. To this end, allogeneic naïve CD4
+CD25
-
T cells were pre-loaded with the fluorescent dye CFDA-
SE and were then cultured with patient DC or mono-
cytes at escalating ratios. As shown in Additional file 2,
T-cell proliferation as detected by the progressive halv-
ing of CFDA-SE fluorescence was superimposable under
the culture conditions here established, suggesting that
the alloantigen-presenting capacity of in vitro differen-
tiated DC-like cells was unaffected by the in vivo expo-
sure to pegfilgrastim. In a further set of experiments,
either pre- or post-pegfilgrastim serum were supplemen-
ted to allogeneic MLR cultures to assess whether soluble
factors in post-pegfilgrastim serum regulate an ongoing
T-cell response to monocytes from third-party healthy
donors. As shown in Figure 6C, the provision of post-
pegfilgrastim serum (days +7 and + 11) to an allogeneic
MLR culture translated into higher levels of T-cell pro-
liferation compared with cultures supplemented with
post-filgrastim serum collected at the same time-points
(Figure 6C and 6D). Modeling of CFDA-SE profiles
reinforced the concept that higher percentages of undi-
vided, parental cells were contained within MLR cul-
tures supplemented with serum from patients receiving
filgrastim [see Additional file 3], thus suggesting that
pegfilgrastim-induced soluble factors were less likely to
restrain T-cell proliferative responses in vitro than fil-
grastim-elicited immune suppressive mediators [18].
Discussion
It is conceivable that the G-CSF formulations currently
available for clinical use differentially affect WBC num-
ber and function. For instance, a direct comparison of
lenograstim (nonglycosylated G-CSF) and filgrastim or
pegfilgrastim with regard to neutrophil phenotype and
function indicated that neutrophils primed with leno-
grastim are less functional and structurally more imma-
ture compared with those primed with filgrastim and, to
a lesser extent, pegfilgrastim [26]. Importantly, rando-
mized clinical trials evaluating single administration of
pegfilgrastim vs. daily filgrastim as an adjunct to che-
motherapy in patients with hematological and solid
malignancies reported similar efficacy profiles [27] or
even a lower overall rate of febrile neutropenia in
patients treated with pegfilgrastim compared with those
given daily filgrastim [28].
The present study aimed to address whether pegfil-
grastim given as prophylaxis for chemotherapy-induced
neutropenia affects the number and function of immune
cells, a finding with potential implications for the treat-
ment of cancer patients. The immune modulating
actions of unconjugated G-CSF have been previously
described both in vitro and ex vivo [29]. This basic
knowledge has been translated into animal models of
autoimmune disorders to skew the immune response
and to promote tolerance. For instance, G-CSF amelio-
rated experimental autoimmune encephalomyelitis [30],
type 1 diabetes [31], experimental colitis [32] and lupus
nephritis [33] through effects on adaptive and innate
immune responses. A pilot clinical trial in Crohn’sd i s -
ease provided proof of principle in favor of immune reg-
ulatory effects by filgrastim in the human setting [34].
In this study, daily treatment with G-CSF for 4 weeks
was correlated with an increase of IL-10-secreting type
1 Treg cells in the peripheral blood and with the accu-
mulation of plasmacytoid DC in the gut lamina propria
[34].
In the present report, WBC and ANC recovery in
patients treated with pegfilgrastim occurred without the
fluctuations associated with daily filgrastim injections.
The administration of pegfilgrastim translated into a
transient but significant elevation of CD34-expressing
HSC, lymphocytes and monocytes. Lymphocyte recircu-
lation is expected to favorably impact on the immune
control of the underlying malignancy, and the
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higher relapse-free survival in cancer patients [35]
underpins the potential clinical significance of the pegfil-
grastim-induced changes in WBC subsets. Pegfilgrastim
did not elicit any appreciable mobilization of Treg cells,
as documented by serial measurements of the frequency
of circulating CD4
+FoxP3
+ Treg cells. We cannot rule
out the possibility that any G-CSF-induced recirculation
of Treg cells was obscured by the high frequency of
Treg cells already measured at baseline. Of interest, fil-
grastim has been reported to increase the frequency of
CD4
+CD25
high Treg cells only when given to cancer
patients in combination with cyclophosphamide as HSC
mobilization regimen [36]. In healthy donors, the phe-




cells may be unaffected by G-CSF [37]. At variance with
human data, filgrastim recruited functional TGF-b-
expressing Treg cells to the pancreatic lymph nodes of
NOD mice, with the likely aim to restrain the prolifera-
tion and function of diabetogenic T cells [31]. It remains
to be determined whether Treg recirculation and/or
recruitment to sites of inflammation and tissue injury
Figure 6 Functional features of Mo-DC from patients receiving pegfilgrastim. Monocytes were purified from the peripheral blood of
patients given pegfilgrastim and were cultured in the presence of either pre-G-CSF or post-G-CSF serum (20% v/v) for 6 days, as detailed in
Materials and Methods. Control cultures consisted of immunogenic DC preparations that were differentiated with GM-CSF and IL-4 without the
provision of additional maturation stimuli (
GM4DC). Panel A: Uptake of FITC-conjugated dextran by monocytes cultured in vitro in the presence
of pre-pegfilgrastim serum (day 0) or post-pegfilgrastim serum (days +7 and +11). Median values and interquartile range are shown. *p < 0.05
compared with Mo-DC differentiated with GM-CSF and IL-4; §p < 0.05 compared with cells cultured with pre-G-CSF serum. Panel B:
Representative experiment; red histograms depict the uptake of FITC-conjugated dextran by monocytes kept at 4°C (negative control) and
empty histograms depict the uptake of FITC-conjugated dextran by the monocyte preparations kept at 37°C. Panel C: CD4
+CD25
- T cells and
monocytes were purified from the peripheral blood of healthy donors as detailed in the main text. After irradiation, monocytes were cultured
with CFDA-SE loaded, allogeneic T cells at a fixed monocyte-to-T cell ratio (1:27) for 7 days, either in the absence or presence of patient serum
(20% v/v). The proliferation index of T-cell cultures established in the presence of patient serum collected before and after G-CSF administration
is shown. The bars depict median and interquartile range recorded in 3 independent experiments performed in duplicate. Panel D: Results of a
representative experiment out of 3 with similar results. The percentage of parental, undivided cells (U; depicted in blue) is indicated. The analysis
of CFDA-SE fluorescence was performed with the proliferation wizard of the ModFit software package, as previously detailed [12].
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administration.
We were also interested in evaluating whether pegfil-
grastim induced the release of immune suppressive HGF
and TGF-b1. HGF is a pro-angiogenic and tumor-pro-
moting cytokine. HGF reportedly skews DC function,
driving an IL-10-secreting tolerogenic profile both in
mice [38] and in humans [8]. We measured significantly
elevated levels of HGF in patients treated with either
pegfilgrastim or filgrastim. Furthermore, HGF secretion
was significantly lower after pegfilgrastim compared
with daily filgrastim administration. In contrast, serum
TGF-b1 levels were not modified by either G-CSF for-
mulation. The observation that HGF induces functional
IDO1 in human monocyte-derived DC [8] raised the
previously unexplored possibility that pegfilgrastim may
indirectly activate IDO1-mediated Trp breakdown into
immune suppressive derivatives, collectively referred to
as Kyn. Interestingly, serum Kyn were not significantly
different when comparing samples at baseline with
those obtained from patients receiving pegfilgrastim. It
should be noted that baseline Kyn levels in our patient
cohort were higher than those measured in healthy con-
trols (median Kyn concentration = 1.86 μM; number of
samples = 20), probably reflecting the expression of
functional IDO1 by the ovarian and endometrial cancer
cells [39]. Also, mRNA signals for IDO1 in monocytes
and granulocytes, a potential source of IDO1 activity
[40], were unchanged when comparing pre-G and post-
G samples. These observations are backed by a recent
study indicating that G-CSF-mobilized immature mye-
loid cells inhibit alloreactive responses in mice through
an IDO-independent mechanism, and that G-CSF sig-
naling is incapable of directly inducing IDO [41].
The studies published so far suggest that the extent of
DC1/DC2 mobilization by filgrastim crucially depends
on the intensity of the mobilization regimen and on the
underlying neoplastic disorder. In this respect, filgrastim
preferentially mobilized DC2 in healthy donors [10] but
failed to impact on the DC1/DC2 ratio in patients with
hematological and solid malignancies [42]. In another
study with healthy donors, low-dose G-CSF (8-10 μg/
kg/day) increased the frequency of CD123
+ blood DC
precursors but mobilized CD11c
+ DC only occasionally
[43]. Furthermore, high-dose G-CSF (30 μg/kg/day)
mobilized CD123
+ DC in patients with multiple mye-
loma but only occasionally in those affected by non-
Hodgkin’s lymphoma, and exerted varying effects on
CD11c
+ DC [43]. We have shown herein that pegfilgras-
tim mobilized both DC1 and DC2 precursors into the
peripheral blood of patients with gynecological malig-
nancies treated with carboplatin and paclitaxel, suggest-
ing lack of DC skewing in vivo. The highest frequencies
of DC1 precursors were measured on day +7 from
pegfilgrastim administration, whereas DC2 precursors
were higher in day +11 samples and declined thereafter.
It is conceivable that different chemotherapy/growth
factor combinations and doses and/or intrinsic charac-
teristics of the underlying neoplastic disorder account
for differences in the relative proportion of DC1/DC2
precursors and in their mobilization kinetics. It is pre-
sently unknown whether the transient DC1 mobilization
induced by pegfilgrastim will impact on the host
immune system’s ability to control disease progression.
IL-12, a prototype member of a family of IL-12-related
cytokines that includes IL-23 and IL-27, is an instigator
of Th1 immune responses and possesses in vivo anti-
tumor activities [44]. IL-12 is a heterodimer formed by a
35-kDa light chain (known as p35 or IL-12a)a n da4 0 -
kDa heavy chain (known as p40 or IL-12b). Messenger
RNA encoding IL-12p35 is present in many cell types,
whereas mRNA encoding IL-12p40 is restricted to cells
that produce the biologically active heterodimer [45].
DC and monocytes have been reported to secrete a 10-
1,000 fold excess of IL-12p40 compared with IL-12p75
[44]. A report on post-transplantation immune functions
in 43 patients receiving filgrastim has shown that cyto-
kine administration delays the reconstitution of CD4
+ T
cells and blunts anti-fungal T-cell responses [25]. These
abnormalities were correlated with the inability of DC
and monocytes from G-CSF-treated patients to release
IL-12p40 [25]. Interestingly, the in vivo immune modu-
lating effects of G-CSF were replicated in vitro when
monocytes from normal volunteers were differentiated
along the DC lineage after their 24-hour pre-treatment
with exogenous G-CSF. Under these conditions, IL-
12p40 production was inhibited both at the mRNA and
protein level [25]. In our study, pegfilgrastim administra-
tion was associated with a significant increase of the
inducible IL-12p40 subunit in patient serum. In patients
given filgrastim, IL-12p40 slightly declined and returned
to baseline values by day +11 from the commencement
of cytokine treatment. Interestingly, neutrophil-derived
serine proteases have been reported to inactivate human
growth factors such as TNF-a at sites of inflammation
and to promote the formation of cytokine split products
[46]. It is tempting to speculate that immunoreactive IL-
12 in patients given filgrastim may have been degraded
as a result of sharp increases in circulating PMN capable
of releasing proteolytic enzymes. Intriguingly, monocytes
from patients treated with pegfilgrastim released higher
amounts of both IL-12p40 and IL-12p70 in vitro com-
pared with monocytes from filgrastim-treated patients.
In contrast, the LPS-induced release of IL-10 increased
to a similar extent in cultures established with mono-
cytes from patients given pegfilgrastim and filgrastim.
IL-12p40 homodimers may behave as IL-12 receptor
antagonists both in mice and in humans, inhibiting IL-
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that post-pegfilgrastim monocytes release higher
amounts of bioactive IL-12p70 compared with post-fil-
grastim monocytes supports the conclusion that pegfil-
grastim may not dampen in vivo anti-tumor immunity
and/or host defense against infectious agents, a response
that crucially depends on the balance between IL-12
and IL-10 production. It has been reported that 6-sulfo
LacNAc
+ DC, a major source of IL-12 and potent indu-
cers of T-cell responses in vitro, are efficiently mobilized
in healthy donors given G-CSF at 7.5 μg/kg of body
weight [49]. Conceivably, pegfilgrastim might also favor
the mobilization of 6-sulfo LacNAc
+ DC or other as yet
unrecognized monocyte/DC populations with a unique
ability to produce bioactive IL-12.
It is known that unconjugated G-CSF promotes the
development of tolerogenic DC in vitro [11] and in vivo
[31]. We showed herein that pegfilgrastim-induced solu-
b l ef a c t o r sp r o m o t e dt h ee m e r g e n c eo fm a t u r eD C - l i k e
populations with high expression of costimulatory mole-
cules (CD80, CD86), CD83 and CD209, and with low
endocytic capacity. Post-pegfilgrastim DC-like cells also
up-regulated ILT3, an inhibitory receptor detected on
anergizing DC preparations [50,51], and yet activated the
proliferation of allogeneic naïve T cells to a similar extent
as immunogenic DC. It should be noted that ILT3
expression may be dispensable for the induction of CD4
+CD25
+ Treg cells by 1,25-dihydroxyvitamin D3 [52],
indicating that molecular determinants of T-cell suppres-
sion other than ILT3 may be operational depending
upon the experimental system. Of potential interest, we
measured high levels of IL-10 in post-pegfilgrastim DC
cultures (317 ± 140 pg/ml compared with 27.1 ± 2.3 pg/
ml in control cultures of immunogenic
GM4DC). IL-10
secretion may have been responsible for ILT3 up-regula-
tion on post-pegfilgrastim monocytes, in line with the
effect of exogenous IL-10 on ILT3 expression by human
vascular endothelial cells [53]. We also evaluated the abil-
ity of post-pegfilgrastim DC to activate allogeneic T-cell
responses in vitro. Interestingly, monocytes from patients
given pegfilgrastim induced T-cell proliferation to a simi-
lar extent as immunogenic DC. In line with this, T-cell
proliferation in response to allogeneic monocytes was
not inhibited by the provision of post-pegfilgrastim
serum to the MLR culture. Our observations on in vitro
DC phenotype and function reinforce the view that peg-
filgrastim and filgrastim differ in their ability to skew
monocyte function, with the former supporting the in
vitro development of activating DC and the latter favor-
ing the emergence of tolerogenic DC preparations [18].
Conclusions
Taken together, the experimental evidence herein pre-
sented indicates that the administration of pegfilgrastim
to hasten neutrophil recovery should not translate into
undesired immune suppression in cancer-bearing
patients, who might benefit from robust monocytic pro-
duction of IL-12, in the absence of excessive induction
of immune suppressive IL-10 and HGF. A further impli-
cation of our findings pertains to HLA-matched stem
cell transplantation, a clinical context where pegfilgras-
tim administration may modulate the number of
immune cells and/or levels of immune regulatory solu-
ble factors, thus ameliorating leukemia clearance. In this
respect, it has been shown that multiple pegylation of
G-CSF imparts an enhanced biological activity with
respect to immune cells and improves stem cell trans-
plant in mice [54]. Intriguingly, multi-pegylated versions
of G-CSF separate GVHD from graft-versus-leukemia
(GVL) through the activation of invariant NKT cells,
thus contributing to leukemia eradication [55,56]. These
considerations add to the knowledge that pegfilgrastim
h a sa d v a n t a g e so v e rf i l g r a s t i mi nt e r m so fp a t i e n tc o m -
pliance, ease of administration and patient quality of life
[1]. Whether the pegfilgrastim-induced modulation of
immune function will favorably impact on disease con-
trol in cancer-bearing patients remains to be prospec-
tively determined.
Additional material
Additional file 1: Expression of IDO1 mRNA and serum Kyn levels in
patients given pegfilgrastim. Panel A: Expression of IDO1 mRNA in
patient monocytes and granulocytes. Details on RNA extraction and
reverse-transcription were previously published [8]. The following primers
were used for mRNA amplification: 5’-ACTGCCCCTGTGATAAACTGTGG-3’
and 5’-GCGTGTGCCATTCTTGTAGTCTG-3’ (human IDO1; GI 156071492); 5’-
TGACATCAAGAAGGTGGTGA-3’ and 5’-TCCACCACCCTGTTGCTGTA-3’
(human GAPDH; GI 7669491). Primer sets were designed using the
Beacon Design Software (Version 3) and the sequences available in the
Gene Bank™ database. All nucleotide primers were synthesized by MWG
(Florence, Italy), and PCR products were analyzed on 3% agarose gel
(Agarose, type XII: low viscosity for beading, Sigma Aldrich) stained with
ethidium bromide. M = marker. + = normal endometrial tissue used as
positive control for IDO1 mRNA expression. Panel B: Quantitative
densitometry (Quantity One software; Bio-Rad, Hercules, CA) is shown
with monocytes and granulocytes isolated from 2 patients given
pegfilgrastim. Insufficient numbers of cells were available on day +7, and
PCR analyses were performed with patient material obtained on days 0,
+11 and +21. Normal endometrial tissue was used as positive control for
IDO1 mRNA expression (red column). Panel C: Serum Kyn levels were
measured by RP-HPLC in 5 patients before (day 0) and after pegfilgrastim
administration (days +7, +11 and +21), as detailed in Materials and
Methods. Data from each individual patient have been plotted using a
different color. The dotted line indicates the median serum Kyn
concentration measured in 50 healthy subjects (2.3 μM).
Additional file 2: T-cell stimulation by Mo-DC generated in vitro
after in vivo administration of pegfilgrastim. Mo-DC were
differentiated from patient monocytes in the presence of either pre-G-
CSF serum or post-G-CSF serum (collected on day + 11), as detailed in
Materials and Methods. Immunogenic DC were generated with IL-4 and
GM-CSF, in accordance with established DC differentiation protocols [17].
The Mo-DC preparations were co-cultured with CFDA-SE pre-loaded,
allogeneic naïve CD4
+CD25
- T cells at different T cell-to-DC ratio. The
percentage of CD25-expressing, CFDA-SE
dim and CFDA-SE
bright cells is
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shown.
Additional file 3: Cell proliferation tracking after provision of post-
G-CSF serum to MLR cultures. MLR cultures were established as above
detailed. T cells and monocytes were plated at a fixed DC-to-T cell ratio
(1:27). The percentage of proliferating T cells residing within each cell
generation (G) was calculated with the proliferation wizard of the
ModFit™ software. Median values and interquartile range are shown.
*denotes a p value < 0.05 when comparing the percentage of parental
(P), undivided cells in MLR cultures established with serum from patients
given pegfilgrastim (black bars) or filgrastim (empty bars).
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